SandpiperSandpiperSandpiperSandpiper
  • Expertise
  • People
  • Careers
  • News & Insights
  • Contact
Sandpiper Promotes Kim Spear to Deputy General Manager of its Hong Kong Office
Sandpiper Promotes Kim Spear to Deputy General Manager of its Hong Kong Office
December 20, 2022
China’s Reopening: What It Means for Asia Pacific and the World
China’s Reopening: What It Means for Asia Pacific and the World
January 18, 2023

Public Affairs Tracker: Global Vaccine Market Report 2022

January 11, 2023
Categories
  • Government and Public affairs
  • Health
Tags
  • policy monitoring
  • public health
  • vaccine
Public Affairs Tracker: Global Vaccine Market Report 2022
News & insights

Public Affairs Tracker: Global Vaccine Market Report 2022

January 2023

Public Affairs Tracker: Global Vaccine Market Report 2022

By Jean Angus, a Director of Sandpiper Health based in Singapore. Jean has 20 years of experience across marketing, journalism and PR. Her areas of expertise include corporate communications, content development, government engagement, patient education, policy development, public health, research, issues and crisis management.


The World Health Organization (WHO) launched its Global Vaccine Market Report 2022 on 9 November 2022. Last published in 2020, this year’s report focuses heavily on the lessons learnt from COVID-19, and its implications for future pandemics. Sandpiper has seen firsthand the important role of public affairs and government relations in supporting clients with their COVID-19 vaccine rollouts across Asia. We take a look at some of the key points raised in the report:

COVID-19 vaccines’ speed to market proves that development of new vaccines against key diseases can be accelerated.

Close collaboration between vaccine developers and regulators moved the COVID-19 vaccines from clinical development to distribution in just 11 months, compared to the industry average of 10 years. The same could theoretically be done for vaccines for other diseases with high burdens such as zika and lassa fever. However, this requires resolving the mismatch between vaccine developers’ commercial priorities and global health priorities identified by the WHO, which has resulted in scant pipelines, slow R&D, and delayed availability.

Resolving supply insecurity is key to meeting global public health needs.

Globally, 10 manufacturers provide 70% of the world’s supply of vaccine doses, accounting for 85% of global value. High-impact vaccines such as those for human papillomavirus and measles, mumps and rubella are made by only a few suppliers with manufacturing bases in a handful of countries, making fast and equitable distribution challenging.

Government investment in vaccine infrastructure and a commitment to attracting private investments, upskilling workforces and developing the local ecosystem will increase the attractiveness of new regional manufacturing sites. Technology transfer programmes such as those by the Developing Country Vaccine Manufacturers Network will also support low- and middle-income countries in acquiring the expertise to manufacture vaccines locally.

Commitment to the greater good is needed to improve vaccine equity.

Despite efforts of COVAX to coordinate global supply and distribution of COVID-19 vaccines, only 12% of total deliveries were done through the facility. The majority of doses have gone to higher-income countries through individual contracts. While several of these countries have engaged in vaccine swap deals to avoid wastage and boost vaccination rates, greater overall commitment to equitable and efficient vaccine distribution is critical for future pandemics.

Better planning by governments will facilitate investments, diversify access to vaccines, promote universal vaccination, and reduce vaccine hesitancy.

On the demand side, governments need to make a strong commitment to a national vaccination agenda, which will enable them to plan and fund vaccination programmes and take advantage of pooled procurement initiatives. Better planning also allows developing countries to take advantage of funding mechanisms such as those by Gavi to increase access to new and underutilised vaccines.

The WHO’s call for a new paradigm in vaccine development and access will necessitate the involvement of every stakeholder within the vaccine ecosystem. As the world increasingly returns to pre-COVID life, it is timely for governments, vaccine makers and non-government organisations alike to reexamine their priorities, find alignment with global public health needs, and leverage this growing emphasis on vaccine equity.


Related news & insights:

Sandpiper Healthcare Tracker 2022
Share

BEIJING
Suite 1105, Full Tower,
No. 9 Middle East 3rd Ring Road,
Chaoyang District, Beijing, PRC

北京市朝阳区东三环中路9号
富尔大厦1105室

+ 86 10 8591 0056
beijing@sandpipercomms.com

HONG KONG
21/F, The Workst@tion,
43 Lyndhurst Terrace, Central,
Hong Kong

香港中環擺花街43號
The Workst@tion 21樓

+852 3114 6339
hongkong@sandpipercomms.com

NEW ZEALAND
The Hive 2/200,
Market Street North, Hawkes Bay,
New Zealand

+64 21084 40939
newzealand@sandpipercomms.com

SHANGHAI
No 1229 Century Avenue, 6/F, Tower 1.
Century Metropolis.
Pudong New District. Shanghai. 200122

世纪大道1229号, 世纪大都会6层,
浦东新区, 上海市, 上海市, 200122

+86 15507577095
shanghai@sandpipercomms.com

SINGAPORE
#21-02, Prudential Tower, 30 Cecil Street,
Raffles Place, Singapore, 049712

+65 6592 2883
singapore@sandpipercomms.com

SYDNEY
Gateway Tower,
36/1 Macquarie Place, Sydney
NSW 2000, Australia

+612 9098 4321
sydney@sandpipercomms.com

OUR AFFILIATE NETWORK
Bangkok
Berlin
Brusels
Dubai
Frankfurt
Hanoi
Ho Chi Minh City
Jakarta
Kuala Lumpur
London
Manila
Mumbai
New York
Paris
San Francisco
Seoul
Taipei
Tokyo
Yangon
Zurich
logo

OUR AFFILIATE NETWORK
Bangkok Berlin Brussels Dubai Frankfurt Hanoi Ho Chi Minh City Jakarta Kuala Lumpur London  
Manila Mumbai New York Paris San Francisco Seoul Taipei Tokyo Yangon Zurich

Copyright © Sandpiper Terms of Use Privacy Policy